Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
* Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 12, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:678...
2022-01-13 00:00
2045
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
* ALA-1000 is the first, three-month slow-release Buprenorphine injection. * Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. * ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treat...
2021-03-10 00:00
1510
